American Journal of Hematology · 1994 · 24 citations · 22 references
MedicineHematologyPharmacologyHemostasisPharmacodynamicsVascular SurgeryAnticoagulant TherapyAntithrombotic TherapyHemostatic AgentsThrombin GenerationThrombosisThrombosis PreventionActivated Partial Thromboplastin Time ProlongationBleedingBleeding Time AssessmentBleeding Time PhysiologyPharmacologic ThromboprophylaxisRecombinant ThrombomodulinThrombosis MechanismsThrombosis Pathophysiology
We examined the antithrombotic effect of recombinant human soluble thrombomodulin (rhs-TM) using an arteriovenous shunt thrombosis model and its influence on hemostasis in rats. Intravenous administration of rhs-TM (0.5-4 mg/kg) significantly inhibited thrombus formation and prolonged ex vivo activated partial thromboplastin time (APTT) in a dose-dependent manner. Thrombus formation was inhibited to the same extent in animals treated with heparin (25-200 U/kg) and in those treated with rhs-TM (0.5-4 mg/kg), but heparin had a much stronger effect on prolonging APTT. In the hemorrhagic study using the rat template bleeding time method, rhs-TM exhibited the prolongation of the bleeding time only at the highest effective dose (rhs-TM; 4 mg/kg) of the thrombosis experiments. Thus, rhs-TM exhibits the inhibitory effect on thrombus formation with less APTT prolongation in comparison with heparin and without significant pertubation of hemostasis.
22
Inactivation of human coagulation factor V by activated protein C.
Koji Suzuki, Johan Stenflo, Björn Dahlbäck et al. · Journal of Biological Chemistry · 1983 · 375 citations · Full text